INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Thursday announced positive results from a Phase 2 trial evaluating eloralintide in adults with obesity or overweight.
The study achieved its primary endpoint, showing mean weight reductions ranging from 9.5% to 20.1%, compared with 0.4% for placebo.
Lilly said it plans to initiate Phase 3 studies of eloralintide as a monotherapy for obesity treatment by the end of 2025.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
